Uniqure (NASDAQ:QURE) Releases Quarterly Earnings Results, Misses Estimates By $0.31 EPS

Uniqure (NASDAQ:QURE) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.31), MarketWatch Earnings reports. The business had revenue of $1.54 million during the quarter, compared to the consensus estimate of $17.87 million. Uniqure had a negative net margin of 2,553.30% and a negative return on equity of 42.00%.

Shares of NASDAQ QURE opened at $41.73 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.89 and a quick ratio of 12.89. The stock has a market capitalization of $1.85 billion, a P/E ratio of -13.29 and a beta of 1.24. Uniqure has a 1-year low of $36.20 and a 1-year high of $76.69. The business has a fifty day moving average price of $49.97 and a 200 day moving average price of $55.53.

In related news, insider Robert Gut sold 26,875 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $70.00, for a total transaction of $1,881,250.00. Also, CEO Matthew C. Kapusta sold 5,626 shares of the company’s stock in a transaction on Wednesday, July 22nd. The stock was sold at an average price of $42.31, for a total value of $238,036.06. Following the sale, the chief executive officer now owns 298,525 shares of the company’s stock, valued at $12,630,592.75. The disclosure for this sale can be found here. Insiders have sold a total of 40,002 shares of company stock valued at $2,614,652 over the last 90 days. 2.66% of the stock is currently owned by company insiders.

Several equities analysts have commented on the company. Zacks Investment Research raised Uniqure from a “hold” rating to a “buy” rating and set a $52.00 price objective on the stock in a research report on Tuesday, June 30th. Wells Fargo & Co downgraded Uniqure from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $90.00 to $56.00 in a research report on Thursday, June 25th. Chardan Capital cut their price objective on Uniqure from $105.00 to $80.00 and set a “buy” rating on the stock in a research report on Thursday, June 25th. Mizuho reaffirmed a “hold” rating and issued a $61.00 price objective on shares of Uniqure in a research report on Tuesday, July 14th. Finally, BidaskClub downgraded Uniqure from a “sell” rating to a “strong sell” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $73.92.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Earnings History for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.